FIELD: bioinformatics.
SUBSTANCE: disclosed is a method of determining activity of a cell signaling path based on expression levels of at least three target genes, as well as a device for realizing such a method.
EFFECT: this group of inventions can be used in diagnosing various diseases.
10 cl, 42 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ASSESSMENT OF ACTIVITY OF CELL SIGNALING PATHWAYS USING A LINEAR COMBINATION(S) OF TARGET GENE EXPRESSION | 2013 |
|
RU2721130C2 |
| COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY | 2016 |
|
RU2771624C2 |
| HSD17B13 OPTIONS AND THEIR APPLICATIONS | 2018 |
|
RU2760851C2 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
| COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
| PEPTIDE IMMUNOGENS AND COMPOSITIONS CONTAINING SAID IMMUNOGENS TARGETING MEMBRANE-BOUND IGE FOR TREATING IGE-MEDIATED ALLERGIC DISEASES | 2017 |
|
RU2769983C2 |
| RISK ASSESSMENT BASED ON EXPRESSION OF HUMAN 4D PHOSPHODIESTERASE OPTION 7 | 2017 |
|
RU2766885C2 |
| DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED ACTION AND MODELING OF DISEASES AND DISORDERS OF POSTMITOTIC CELLS | 2014 |
|
RU2725502C2 |
| CRISPR-CAS SYSTEMS AND METHODS FOR CHANGING THE EXPRESSION OF GENE PRODUCTS | 2013 |
|
RU2796273C2 |
| PEPTIDE IMMUNOGENS FROM C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND COMPOSITIONS BASED ON THEM FOR TREATMENT OF SYNUCLEONOPATHIES | 2018 |
|
RU2810774C2 |
